{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-297978","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2022-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.780681+00:00","generated_at":"2026-06-21T09:58:53.716238+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veru reports FY2022 net loss $83.8M; sabizabulin EUA faces FDA advisory panel 8-5 vote against","bullets":["Full-year net loss $83.8M ($1.05 diluted EPS) vs net income $7.4M in FY2021.","Total net revenues fell to $39.4M from $61.3M; FC2 product sales decline cited.","R&D spending surged to $70.6M from $32.7M on sabizabulin and oncology programs.","FDA advisory committee voted 8-5 against sabizabulin EUA; final FDA decision pending.","Cash and equivalents $80.2M at Sept. 30, 2022, down from $122.4M a year earlier."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-297978","json":"https://secwatch.observer/filing/0001193125-22-297978.json","markdown":"https://secwatch.observer/filing/0001193125-22-297978.md","text":"https://secwatch.observer/filing/0001193125-22-297978.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312522297978/0001193125-22-297978-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312522297978/d384863d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T09:58:53.716238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84cefbc519eb241ece6fdd08acd96334c1cda3df","claim":"VERU INC. reported financial results for fiscal 2022 fourth quarter and full year ended September 30, 2022.","evidence_excerpt":"Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced financial results for its fiscal 2022 fourth quarter and full year ended September 30, 2022 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/863894/000119312522297978/0001193125-22-297978-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2022 fourth quarter and full year ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}